Vaccines for bluetongue
- PMID: 8893989
- DOI: 10.1111/j.1751-0813.1996.tb10036.x
Vaccines for bluetongue
Abstract
Isolation of 8 serotypes of bluetongue virus (BTV) in Australia has led to widespread debate on how to prepare for an outbreak of bluetongue disease and the type of vaccine best suited to control bluetongue in Australia. This article describes the vaccine options under consideration by research workers and animal health administrators. The most widely discussed options are live attenuated virus, killed virus and virus-like particles (VLP) generated by recombinant baculoviruses. Attenuated virus vaccines are cheap and easy to produce and are administered in a single dose. They replicate in sheep without causing significant clinical effects and provide protection against challenge with virulent virus of the same serotype. The possibility that insects could acquire vaccine virus by feeding on vaccinated animals and transmit it to sheep or cattle cannot be eliminated. This poses a risk because attenuated viruses are teratogenic if ewes are infected in the first half of pregnancy. In addition, vaccine virus replication in insects and ruminants may lead to a reversion to virulence. Killed virus vaccines have been shown to be efficacious in small laboratory trials and cannot be transmitted to other animals in the field, but are significantly more expensive to produce than attenuated viruses and require at least 2 doses with adjuvant to elicit an immune response. More work is needed to properly assess their effectiveness and determine their cost of production. Recombinant VLP contain the 4 major structural proteins of BTV but no nucleic acid. VLP are relatively easy to isolate, but it is unlikely that the purification methods currently used in laboratories will be adapted for use commercially. Despite the enthusiasm of recent years, little commercial progress appears to have been made. Although scientific research in Australia and overseas has provided a number of options for development of bluetongue vaccines, the decisions on which to use in an outbreak are complex and will require, not only consideration of factors discussed here, but also agreement from industry and government.
Similar articles
-
Vaccines against bluetongue in Europe.Comp Immunol Microbiol Infect Dis. 2008 Mar;31(2-3):101-20. doi: 10.1016/j.cimid.2007.07.006. Epub 2007 Aug 31. Comp Immunol Microbiol Infect Dis. 2008. PMID: 17765305
-
Comparison of the humoral response between sheep vaccinated with a killed-virus vaccine and those vaccinated with a modified-live virus vaccine against bluetongue virus serotype 17.J Am Vet Med Assoc. 2016 May 1;248(9):1043-9. doi: 10.2460/javma.248.9.1043. J Am Vet Med Assoc. 2016. PMID: 27074613 Clinical Trial.
-
Evaluation of the immunogenicity of an experimental subunit vaccine that allows differentiation between infected and vaccinated animals against bluetongue virus serotype 8 in cattle.Clin Vaccine Immunol. 2013 Aug;20(8):1115-22. doi: 10.1128/CVI.00229-13. Epub 2013 May 29. Clin Vaccine Immunol. 2013. PMID: 23720365 Free PMC article.
-
Vaccines for Prevention of Bluetongue and Epizootic Hemorrhagic Disease in Livestock: A North American Perspective.Vector Borne Zoonotic Dis. 2015 Jun;15(6):385-96. doi: 10.1089/vbz.2014.1698. Vector Borne Zoonotic Dis. 2015. PMID: 26086559 Review.
-
Bluetongue vaccines: the past, present and future.Expert Rev Vaccines. 2009 Feb;8(2):191-204. doi: 10.1586/14760584.8.2.191. Expert Rev Vaccines. 2009. PMID: 19196199 Review.
Cited by
-
Determinants of bluetongue virus virulence in murine models of disease.J Virol. 2011 Nov;85(21):11479-89. doi: 10.1128/JVI.05226-11. Epub 2011 Aug 24. J Virol. 2011. PMID: 21865388 Free PMC article.
-
Oncolytic bluetongue viruses: promise, progress, and perspectives.Front Microbiol. 2011 Mar 16;2:46. doi: 10.3389/fmicb.2011.00046. eCollection 2011. Front Microbiol. 2011. PMID: 21747785 Free PMC article.
-
Immune responses and protective efficacy of binary ethylenimine (BEI)-inactivated bluetongue virus vaccines in sheep.Vet Res Commun. 2006 Nov;30(8):873-80. doi: 10.1007/s11259-006-3313-5. Vet Res Commun. 2006. PMID: 17139537 Clinical Trial. No abstract available.
-
Expression of VP7, a Bluetongue virus group specific antigen by viral vectors: analysis of the induced immune responses and evaluation of protective potential in sheep.PLoS One. 2014 Nov 3;9(11):e111605. doi: 10.1371/journal.pone.0111605. eCollection 2014. PLoS One. 2014. PMID: 25364822 Free PMC article.
-
Opinion of the Scientific Panel on Animal Health and Welfare on request from the Commission on bluetongue.EFSA J. 2008 Jul 23;6(7):735. doi: 10.2903/j.efsa.2008.735. eCollection 2008 Jul. EFSA J. 2008. PMID: 37213828 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical